MedPath

Cetrorelix

Generic Name
Cetrorelix
Brand Names
Cetrotide
Drug Type
Small Molecule
Chemical Formula
C70H92ClN17O14
CAS Number
120287-85-6
Unique Ingredient Identifier
OON1HFZ4BA
Background

Cetrorelix is a man-made hormone that blocks the effects of Gonadotropin Releasing Hormone (GnRH). GnRH controls another hormone that is called luteinizing hormone (LH), which is the hormone that starts ovulation during the menstrual cycle. When undergoing hormone treatment sometimes premature ovulation can occur, leading to eggs that are not ready for fertilization to be released. Cetrorelix does not allow the premature release of these eggs to occur.

Indication

For the inhibition of premature LH surges in women undergoing controlled ovarian stimulation

Associated Conditions
-
Associated Therapies
Controlled Ovarian Stimulation
Clinical Trials
Related News

Progesterone Primed Ovarian Stimulation Versus GnRH Antagonist in With Expected High Ovarian Response Undergoing in Vitro Fertilization

Phase 2
Not yet recruiting
Conditions
IVF
PCO
Interventions
Drug: Dydrogesterone Tablets
Drug: Cetrorelix
First Posted Date
2023-07-19
Last Posted Date
2023-08-03
Lead Sponsor
Beni-Suef University
Target Recruit Count
200
Registration Number
NCT05951400
Locations
🇪🇬

Beni-suef university Hospital, Banī Suwayf, Beni Suef, Egypt

Efficacy and Safety of BG2109 During Controlled Ovarian Hyperstimulation in Female Subjects Undergoing ART Procedures

Phase 2
Not yet recruiting
Conditions
Assisted Reproductive Technology
Controlled Ovarian Hyperstimulation
Interventions
Drug: BG2109
Drug: Cetrorelix
First Posted Date
2023-02-22
Last Posted Date
2023-07-27
Lead Sponsor
Bio Genuine (Shanghai) Biotech Co., Ltd.
Target Recruit Count
240
Registration Number
NCT05738382
Locations
🇨🇳

Site No3, Wuhan, China

🇨🇳

Site No7, Guangzhou, China

🇨🇳

Site No9, Haikou, China

and more 7 locations

Effect of GnRH Agonist vs GnRH Antagonist on Oocyte Morphology in Polycystic Ovary Syndrome Patients During IVF/ICSI

Phase 4
Completed
Conditions
In Vitro Fertilization
Infertility
Intracytoplasmic Sperm Injection
Polycystic Ovary Syndrome
Interventions
Drug: Triptorelin acetate
Drug: Cetrorelix
Drug: recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin
Drug: Human Chorionic Gonadotropin (hCG)
First Posted Date
2021-01-27
Last Posted Date
2023-10-24
Lead Sponsor
Damascus University
Target Recruit Count
50
Registration Number
NCT04727684
Locations
🇸🇾

Orient Hospital, Damascus, Syrian Arab Republic

Effect of GnRH Agonist vs GnRH Antagonist on IVF/ICSI Outcomes in Polycystic Ovary Syndrome Patients.

Phase 4
Completed
Conditions
In Vitro Fertilization
Infertility
Polycystic Ovary Syndrome
Intracytoplasmic Sperm Injection
Interventions
Drug: Triptorelin acetate
Drug: Cetrorelix
Drug: recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin
Drug: Human Chorionic Gonadotropin (hCG)
First Posted Date
2021-01-27
Last Posted Date
2023-10-24
Lead Sponsor
Damascus University
Target Recruit Count
50
Registration Number
NCT04727671
Locations
🇸🇾

Orient Hospital, Damascus, Syrian Arab Republic

Effect of GnRH Agonist vs GnRH Antagonist on IVF/ICSI Outcomes.

Phase 4
Completed
Conditions
In Vitro Fertilization
Infertility
Intracytoplasmic Sperm Injection
Interventions
Drug: Triptorelin acetate
Drug: Cetrorelix
Drug: recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin
Drug: Human Chorionic Gonadotropin (hCG)
First Posted Date
2021-01-26
Last Posted Date
2023-10-24
Lead Sponsor
Damascus University
Target Recruit Count
50
Registration Number
NCT04724343
Locations
🇸🇾

Orient Hospital, Damascus, Syrian Arab Republic

Effect of GnRH Agonist vs GnRH Antagonist on Oocyte Morphology During IVF/ICSI

Phase 4
Completed
Conditions
In Vitro Fertilization
Intracytoplasmic Sperm Injection
Infertility
Interventions
Drug: Triptorelin acetate
Drug: Cetrorelix
Drug: recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin
Drug: Human Chorionic Gonadotropin (hCG)
First Posted Date
2021-01-26
Last Posted Date
2023-10-24
Lead Sponsor
Damascus University
Target Recruit Count
50
Registration Number
NCT04724486
Locations
🇸🇾

Orient Hospital, Damascus, Syrian Arab Republic

Estrogen, Diabetes, and Endothelial Function

Not Applicable
Completed
Conditions
Type 1 Diabetes
Interventions
Drug: Cetrorelix acetate, 0.25 mg/day
Drug: Estradiol Patch, 0.025 Mg/24 Hours Weekly Transdermal Film, Extended Release
Drug: Placebo patch
First Posted Date
2020-06-05
Last Posted Date
2020-06-05
Lead Sponsor
University of Colorado, Denver
Target Recruit Count
40
Registration Number
NCT04418908

Comparison Between Two Different Protocols in Polycystic Ovary Symdrome Women Undergoing Intra-cytoplasmic Injection

Phase 4
Conditions
Polycystic Ovary Syndrome
Interventions
Drug: Cetrorelix
Drug: Leuprolide Acetate
First Posted Date
2019-09-19
Last Posted Date
2020-03-25
Lead Sponsor
Assiut University
Target Recruit Count
150
Registration Number
NCT04094467
Locations
🇪🇬

Ahmed Abbas, Assiut, Cairo, Egypt

Comparison of the Live Birth Rate Between the PPOS and the GnRH Antagonist Protocol in Patients Undergoing IVF

Not Applicable
Recruiting
Conditions
ART
Infertility
Interventions
Drug: Duphaston
Drug: Cetrorelix
First Posted Date
2018-09-21
Last Posted Date
2024-08-20
Lead Sponsor
ShangHai Ji Ai Genetics & IVF Institute
Target Recruit Count
784
Registration Number
NCT03680053
Locations
🇨🇳

ShangHai JIAI Genetics&IVF Institute, Shanghai, China

Long Protocol and Freeze All Embryos vs Antagonist Protocol With Fresh Embryo Transfer in PCOS Patients Undergoing ICSI

Phase 4
Completed
Conditions
Invitro Fertilization
Interventions
Drug: Triptorelin
Drug: cetrorelix
Drug: Recombinant Follicle Stimulating Hormone
First Posted Date
2017-04-18
Last Posted Date
2017-11-07
Lead Sponsor
Cairo University
Target Recruit Count
204
Registration Number
NCT03118830
Locations
🇪🇬

Ahmed Maged, Cairo, Egypt

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy